Nucleus Genomics - About the company
Nucleus Genomics is a series A company based in Manhattan (United States), founded in 2021 by Kian Sadeghi. It operates as a Provider of genetic testing kits for rare variant analysis. Nucleus Genomics has raised $32M in funding from Founders Fund. The company has 44 active competitors, including 12 funded and 12 that have exited. Its top competitors include companies like Natera, Lantern Pharma and GeneDx.
Company Details
Provider of genetic testing kits for rare variant analysis. The company offers direct to consumer genetic testing platform that provides genetic risk and disposition score analyses on an extensive number of diseases and traits by leveraging whole-genome sequencing (WGS).
- Website
- mynucleus.com
- Social
Key Metrics
Founded Year
2021
Location
Manhattan, United States
Stage
Series A
Total Funding
$32M in 3 rounds
Latest Funding Round
Investors
Ranked
4th among 44 active competitors
Employee Count
44 as on Aug 31, 2026
Sign up to download Nucleus Genomics' company profile
Nucleus Genomics's funding and investors
Nucleus Genomics has raised a total funding of $32M over 3 rounds. Its first funding round was on Dec 15, 2021. Its latest funding round was a Series A round on Jan 30, 2025 for $*****. 6 investors participated in its latest round. Nucleus Genomics has 13 institutional investors and 16 angel investors.
Here is the list of recent funding rounds of Nucleus Genomics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 30, 2025 | 2662038 | Series A | 4386361 | 5512779 | 5403345 | 1525726 |
Jul 14, 2022 | 3509535 | Series A | 2749982 | 8992589 | 9400978 | |
Dec 15, 2021 | 3181626 | Seed | 1098835 | 7464177 |
Access funding benchmarks and valuations. Sign up today!View details of Nucleus Genomics's funding rounds and investors
Nucleus Genomics' founders and board of directors
Founder? Claim ProfileThe founders of Nucleus Genomics is Kian Sadeghi. Kian Sadeghi is the CEO of Nucleus Genomics.
Here are the details of Nucleus Genomics' key team members:
- Kian Sadeghi: Founder & CEO of Nucleus Genomics. They are also an angel investor in 1 startup.Contact Info: 1 email address
View details of Nucleus Genomics's Founder profiles and Board Members
Nucleus Genomics' employee count trend
Nucleus Genomics has 44 employees as of Aug 26. Here is Nucleus Genomics's employee count trend over the years:
Uncover Nucleus Genomics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Nucleus Genomics's Competitors and alternates
Top competitors of Nucleus Genomics include Natera, Lantern Pharma and GeneDx. Here is the list of Top 10 competitors of Nucleus Genomics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 80/100 | |
2nd |  Lantern Pharma 2013, Dallas (United States), Public | Developing drug and companion diagnostics for multi-drug resistant cancers | $7.12M | 62/100 | |
3rd | GeneDx 2000, Gaithersburg (United States), Acquired | Provider of genetic testing for inherited disorders | - | 62/100 | |
4th |  Nucleus Genomics 2021, Manhattan (United States), Series A | Provider of genetic testing kits for rare variant analysis | $32M | 62/100 | |
5th |  RareCyte 2009, Seattle (United States), Series C | Developer of technologies for the analysis of rare and single cells in the blood | $114M | 57/100 | |
6th |  Rgenta 2018, Cambridge (United States), Series A | Developer of RNA-based therapeutics for multiple disorders | $90M | 56/100 | |
7th | Sema4 2017, Stamford (United States), Public | Provider of genome-based diagnostic testing solutions for reproductive health and oncology | $241M | 56/100 | |
8th | Kiyatec 2005, Pendleton (United States), Series C | Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment | $29.5M | 55/100 | |
9th | Strata Oncology 2015, Ann Arbor (United States), Series C | Precision oncology company enabling smarter cancer treatment through advanced biomarker algorithms | $139M | 55/100 | |
10th |  ArcherDX 2013, Boulder (United States), Acquired | Developer of molecular cancer diagnostic products | $153M | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Nucleus Genomics's competitors? Click here to see the top ones
Nucleus Genomics's Investments and acquisitions
Nucleus Genomics has acquired 2 companies including Cambrean and Impute.me. Nucleus Genomics has not made any investments as of now.Reports related to Nucleus Genomics
Here is the latest report on Nucleus Genomics's geography:
News related to Nucleus Genomics
Filter this listMedia has covered Nucleus Genomics for a total of 4 events in the last 1 year, 3 of them have been about partnerships and 1 about company updates.
•
•
•
•
•
•
•
•
Nucleus Genomics Hires Romain Daguet, Award-Winning Founder and EngineerPR Newswire•Feb 25, 2025•Nucleus Genomics
•
•
Nucleus Raises $14m To Transform Genetic Health TestingAlleyWatch•Jan 30, 2025•Nucleus Genomics, One Eight Capital, Giant Step Capital, Neo
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Nucleus Genomics
Explore our recently published companies
- Quantify Environmental - Guelph based, 2022 founded, Unfunded company
- 3Dscan - Serbia based, 2023 founded, Unfunded company
- IFS - Brazil based, 2006 founded, Unfunded company
- Digital Star - Riyadh based, 2024 founded, Unfunded company
- Grogan Accounting Services - Pell City based, 2003 founded, Unfunded company
- Impulse3D - Beverly Hills based, 2022 founded, Unfunded company
